Oculis to buy Accure rights to Privosegtor for $3.8 million plus up to 2,050,000 shares
OCS•Separate closing for ACT-02 also included
The transaction also includes a separate, later closing for ACT-02, an early-stage preclinical neurology candidate, contingent on the Privosegtor closing.
Privosegtor closing is expected by Feb. 28, 2027, while the ACT-02 closing is expected by March 31, 2027.
Oculis to acquire worldwide rights to Privosegtor
Oculis signed an asset purchase agreement to buy Accure’s worldwide development and commercial rights to Privosegtor (ACT-01).
The deal would terminate the existing Privosegtor license, removing related milestone payments and royalties; Oculis would retain greater economics on future sales.
Consideration includes USD 3.8 million cash upfront at first closing, plus up to 2,050,000 Oculis ordinary shares, including milestone-based earnout shares.
